We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Review · October 20, 2021

Efficacy and Safety of Canakinumab in the Treatment of Adult-Onset Still’s Disease

Seminars in Arthritis and Rheumatism

 

Additional Info

Seminars in Arthritis and Rheumatism
Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review
Semin. Arthritis Rheum. 2021 Aug 27;[EPub Ahead of Print], JM Cota-Arce, J Cota, MA De León-Nava, A Hernández-Cáceres, LI Moncayo-Salazar, F Valle-Alvarado, VL Cordero-Moreno, KL Bonfil-Solis, JE Bichara-Figueroa, J Hernández-Hernández, L Villela

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading